CD8A and neoplasm: Recent research results suggest that a conventional DC1 (cDC1, CD103+ DC in mice and CD141+/BDCA3+ DC in human) has been reported as the only professional antigen-presenting DC that can capture tumor-specific antigen on their MHC class I molecule and cross-present the antigen to CD8+ T cells (15–17).